Felix is hiring an Associate Head of Business Development to help drive partnerships and grow Felix’s ability to develop novel therapies for bacterial infections. You’ll work directly with the CEO and the Head of Business Development and interface with the R&D team to raise non-dilutive funding, create partnership strategies leveraging our phage technology platform, identify and qualify partnership opportunities, and build projects with partners. This role is ideal if you think creatively about applying new technologies and are passionate about working at the nexus of infectious disease, the microbiome, and synthetic biology.
Responsibilities will include: Analyzing potential market opportunities that leverage our phage engineering technology platform; Identifying and qualifying potential funding partners for projects; Organizing and tracking interactions with potential partners; Collaborating with the Head of BD to develop project proposals utilizing Felix’s core technology platform; Contributing to SBIR/STTR proposals and other applications for non-dilutive funding
Requirements for the position include: Degree in a field of biology or business; Communication and collaboration skills needed to work effectively with BD to identify, evaluate, and act on partnership opportunities; Ability to interact with R&D to understand platform capabilities and project scope; Experience in conducting robust analyses on market opportunities and present topline results; Impeccable organization skill for use in managing meeting notes, research articles, and press releases relevant to market opportunities; Ability to solve complex problems with creative solutions; US citizenship or greencard holder
Felix Biotechnology is a diverse team of innovative, creative, and patient-focused researchers ending the threat of antibiotic resistance and transforming treatment across diseases using engineered phage. We are a preclinical stage company developing therapies targeting pathogenic and pathobiontic microbes, with a particular focus on multidrug resistant bacterial infections. Felix’s proprietary discovery, optimization, and engineering platform enables it to link genotype to phenotype and engineer better therapeutic phages. Felix Biotechnology is a graduate of the Y-Combinator (W20) and the Illumina Accelerator (10th Cycle), was winner of 2019 international competition Falling Walls Startup of the Year, recipient of NSF funding, and has active partnerships to develop phage technology for multiple companies.
Felix BiotechnologyUnited States
